Scarica l'app Stockscreener
120.69
3.94%
4.58
Dopo l'orario di chiusura:
120.69
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$116.11
Aprire:
$121.05
Volume 24 ore:
1.92M
Relative Volume:
1.68
Capitalizzazione di mercato:
$12.03B
Reddito:
$2.24B
Utile/perdita netta:
$385.90M
Rapporto P/E:
32.36
EPS:
3.73
Flusso di cassa netto:
$440.10M
1 W Prestazione:
+4.93%
1M Prestazione:
-17.27%
6M Prestazione:
-20.01%
1 anno Prestazione:
-7.62%
Intervallo 1D:
$118.57
$122.37
Intervallo di 1 settimana:
$113.00
$122.37
Portata 52W:
$110.95
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Confronta NBIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
120.69 | 12.03B | 2.24B | 385.90M | 440.10M | 3.73 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now? - Insider Monkey
Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality - Simply Wall St
Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
DSM Capital Partners LLC Has $127.30 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Assessing Neurocrine Biosciences: Insights From 15 Financial Analysts - Benzinga
Huntington's Disease Market Growth to Accelerate in Forecast - openPR
Neurocrine Biosciences sets $500M share buyback plan By Investing.com - Investing.com South Africa
Neurocrine Biosciences sets $500M share buyback plan - Investing.com
Neurocrine Biosciences Approves $500 Million Share Repurchase Program -February 21, 2025 at 08:19 am EST - Marketscreener.com
Neurocrine Board Authorizes Share Repurchase ProgramQuick Facts - Nasdaq
Neurocrine Biosciences (NBIX) Announces $500M Share Buyback - StreetInsider.com
Can Neurocrine's New $500M Buyback Signal Even Stronger Growth Ahead? - StockTitan
Leerink Partnrs Issues Optimistic Outlook for NBIX Earnings - MarketBeat
Rice Hall James & Associates LLC Sells 6,785 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Downgraded to Buy Rating by StockNews.com - MarketBeat
AlphaCentric Advisors LLC Sells 18,816 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences Board Of Directors Authorizes $500 Million Share Repurchase Program - Marketscreener.com
Leerink Partnrs Has Pessimistic View of NBIX Q3 Earnings - MarketBeat
Ieq Capital LLC Increases Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Van ECK Associates Corp Buys 9,824 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
New York State Teachers Retirement System Cuts Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Vontobel Holding Ltd. Has $1.15 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Matt Abernethy Sells 2,558 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock - MarketBeat
Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January - Insider Monkey
Neurocrine Biosciences chief legal officer sells $107,727 in stock - MSN
Neurocrine Biosciences' chief corporate affairs officer sells shares worth $208,387 - MSN
Neurocrine Biosciences CFO Matt Abernethy sells $115,908 in stock - MSN
Neurocrine Biosciences' SWOT analysis: navigating growth amid market shifts By Investing.com - Investing.com Nigeria
Neurocrine Biosciences' SWOT analysis: navigating growth amid market shifts - Investing.com
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Sees Large Drop in Short Interest - MarketBeat
Stanley Laman Group Ltd. Increases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences CHRO sells shares worth $181,129 - MSN
Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 5,844 Shares of Stock - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Trimmed by Allspring Global Investments Holdings LLC - MarketBeat
Julie Cooke Sells 1,551 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock - MarketBeat
Neurocrine Biosciences chief legal officer sells $254,991 in stock - MSN
Stifel maintains Neurocrine Bio stock target, positive on Takeda deal - MSN
Savant Capital LLC Purchases Shares of 16,543 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano Sells 980 Shares - MarketBeat
Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells 2,274 Shares of Stock - MarketBeat
Neurocrine Biosciences chief scientific officer sells $336,238 in stock - MSN
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Position Cut by Fiera Capital Corp - MarketBeat
Neurocrine Biosciences chief commercial officer sells $251,426 in stock - MSN
Neurocrine Biosciences director Sherwin sells $1.6m in stock - MSN
Neurocrine Biosciences CEO sells shares for $298,907 By Investing.com - Investing.com Australia
Neurocrine Biosciences chief corporate affairs officer sells $82,820 in stock - MSN
Neurocrine Biosciences chief commercial officer sells $115,940 in stock - MSN
Neurocrine Biosciences executive sells shares worth $82,792 - MSN
Neurocrine Biosciences director sells $681,913 in stock - MSN
SG Americas Securities LLC Sells 7,022 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.72%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):